Evaxion Biotech A/S (NASDAQ: EVAX) stock fell -1.81% on Monday to $1.63 against a previous-day closing price of $1.66. With 0.3 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.3 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.6500 whereas the lowest price it dropped to was $1.5600. The 52-week range on EVAX shows that it touched its highest point at $3.75 and its lowest point at $1.41 during that stretch. It currently has a 1-year price target of $13.50.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EVAX was up-trending over the past week, with a rise of 5.16%, but this was down by -11.65% over a month. Three-month performance dropped to -45.12% while six-month performance fell -36.82%. The stock lost -56.65% in the past year, while it has lost -8.17% so far this year. A look at the trailing 12-month EPS for EVAX yields -1.09 with Next year EPS estimates of -1.05. For the next quarter, that number is -0.26. This implies an EPS growth rate of -58.80% for this year and -9.40% for next year.
Float and Shares Shorts:
At present, 23.84 million EVAX shares are outstanding with a float of 13.80 million shares on hand for trading. On Dec 29, 2022, short shares totaled 32049.999999999996, which was 0.13% higher than short shares on Nov 29, 2022. In addition to Dr. Niels Iversen Moeller M.D. as the firm’s Co-Founder, VP of Bus. & Director, Mr. Andreas Holm Mattsson serves as its Co-Founder and Chief AI & Culture Officer.
Through their ownership of 1.60% of EVAX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.61% of EVAX, in contrast to 0.01% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in EVAX with 0.46% of the stake, Citadel Securities LLC holds 106,909 shares worth 106,909. A second-largest stockholder of EVAX, Telemetry Investments LLC, holds 29,000 shares, controlling over 0.13% of the firm’s shares. Morgan Stanley & Co. LLC is the third largest shareholder in EVAX, holding 3,496 shares or 0.02% stake. With a 0.01% stake in EVAX, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 2,428 shares are owned by the mutual fund manager.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, EVAX reported revenue of $0.00 and operating income of -$6.26M. The EBITDA in the recently reported quarter was -$4.72M and diluted EPS was -$0.20.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EVAX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EVAX analysts setting a high price target of $18.00 and a low target of $11.00, the average target price over the next 12 months is $14.67. Based on these targets, EVAX could surge 1004.29% to reach the target high and rise by 574.85% to reach the target low. Reaching the average price target will result in a growth of 800.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. EVAX will report FY 2022 earnings on 03/19/2024. Analysts have provided yearly estimates in a range of -$0.95 being high and -$0.97 being low. For EVAX, this leads to a yearly average estimate of -$0.96. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Evaxion Biotech A/S surprised analysts by $0.03 when it reported -$0.24 EPS against a consensus estimate of -$0.27. The surprise factor in the prior quarter was $0.10. Based on analyst estimates, the high estimate for the next quarter is -$0.25 and the low estimate is -$0.28. The average estimate for the next quarter is thus -$0.26.